Bioxytran (BIXT) Share-based Compensation Growth (1y) (2011 - 2026)
Bioxytran (BIXT) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -7.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -8.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -22.43% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 11.71% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -4.01% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 38.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.75% |
| Dec 31, 2025 | 342.16% |
| Sep 30, 2025 | 678.13% |
| Jun 30, 2025 | -567.99% |
| Mar 31, 2025 | -88.05% |
| Dec 31, 2024 | -99.52% |
| Sep 30, 2024 | -89.65% |
| Jun 30, 2024 | 2,869.72% |
| Mar 31, 2024 | 89,818.35% |
| Dec 31, 2023 | 114,058.19% |
| Sep 30, 2023 | 10.63% |
| Jun 30, 2023 | -99.23% |
| Mar 31, 2023 | -96.21% |
| Dec 31, 2022 | 99.34% |
| Sep 30, 2022 | 8,609.36% |
| Jun 30, 2022 | -8.48% |
| Mar 31, 2022 | -97.11% |
| Dec 31, 2021 | -648.42% |
| Sep 30, 2021 | -93.27% |
| Jun 30, 2021 | -59.97% |